“Early and Sustained Treatment Satisfaction Observed in Patients With Moderate to Severe Psoriasis Treated With Ixekizumab: Results From Second Interim Analysis of the Real-World Psoriasis in Special Areas (PSoSA) Study”, J of Skin, vol. 9, no. 1, p. s509, Jan. 2025, doi: 10.25251/skin.9.supp.509.